Title: The prevention of recurrent VTE in patients with cancer
Design: Multicenter, open-label, parallel-group, randomized, controlled trial
Objective: To compare LMWH with warfarin in preventing VTE recurrence in patients with cancer and acute symptomatic VTE
Year of publication: 2003
Inclusion Criteria: patients with any cancer other than basal cell or squamous cell carcinoma and acute symptomatic VTE
Comparison groups: dalteparin (n=338) vs warfarin (n=338)
Conclusion: In patients with cancer, dalteparin reduced VTE recurrence without increasing bleeding risk or deaths compared to warfarin. Source: Lee AY, et al. et al. NEJM, 2003. 349(2):146-53.